Treatment of Stage 2 Breast Cancer

Introduction to Treatment

The National Comprehensive Cancer Network recommends multimodality treatment for stage 2 breast cancer, consisting of surgical resection, sentinel lymph node biopsy or axillary dissection, and adjuvant systemic therapy tailored to hormone receptor and HER2 status 1, 2, 3

Breast-conserving surgery followed by whole breast radiation is the standard approach and provides equivalent survival to mastectomy for most stage 2 patients, with the advantage of superior quality of life (category 1 evidence) 4
Mastectomy with or without reconstruction is indicated when breast-conserving surgery cannot achieve clear margins with satisfactory cosmetic results, when widespread microcalcifications are present, or based on patient preference 5, 6
Sentinel lymph node biopsy is the standard approach for surgical staging of clinically negative axillary nodes in stage 2 disease, as it provides equivalent staging accuracy to full axillary dissection with significantly less morbidity 1, 4

Whole breast radiation therapy is mandatory after lumpectomy (category 1), as it substantially reduces local recurrence rates and improves survival 5, 4
A radiation boost to the tumor bed is standard for patients under 50 years old and should be considered for patients over 50 with risk factors including positive nodes, lymphovascular invasion, or close margins 5, 4, 6
Post-mastectomy radiation to the chest wall and regional lymph nodes is indicated when lymph nodes are involved 5, 1, 2

Adjuvant endocrine therapy is mandatory for all hormone receptor-positive stage 2 breast cancers (category 1) 2, 3
Trastuzumab-based therapy in combination with chemotherapy is required for all HER2-positive stage 2 breast cancers (category 1) 2
Chemotherapy is the only systemic treatment option for triple-negative stage 2 breast cancer 2

For large stage 2 tumors, neoadjuvant systemic therapy should be considered to downsize the tumor and potentially enable breast-conserving surgery instead of mastectomy 1, 2
Neoadjuvant chemotherapy is particularly appropriate for HER2-positive and triple-negative tumors 2

When using neoadjuvant chemotherapy, the typical sequence is: systemic therapy → surgery → radiation → completion of systemic therapy 1, 2
When using adjuvant therapy, the sequence is: surgery → chemotherapy (if indicated) → radiation → endocrine therapy (if hormone receptor-positive) 2, 3
Trastuzumab and endocrine therapy can be administered concurrently with radiation therapy 2

Do not omit radiation therapy after breast-conserving surgery, as this substantially increases local recurrence risk and reduces survival 5, 4
Do not perform routine axillary dissection when SLN biopsy is negative, as this adds morbidity without benefit 1, 4
Do not accept positive surgical margins, as re-excision or mastectomy is required 5, 6
Do not delay endocrine therapy in hormone receptor-positive disease, as it should begin after chemotherapy completion and continue for 5-10 years 2, 3